Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0356 EUR | -15.24% | -30.87% | -98.22% |
Apr. 25 | Pharnext: share price rises on encouraging comments | CF |
Mar. 06 | Pharnext: listing suspended pending further update | CF |
Business Summary
The group has a portfolio of 2 products in clinical development: PXT3003 (treatment of the orphan disease Charcot-Marie-Tooth type 1A) and PXT864 (Alzheimer's disease treatment).
Number of employees: 23
Sales per Business
EUR in Million | 2021 | Weight | 2022 | Weight | Delta |
---|---|---|---|---|---|
Pharmaceutical Therapies
100.0
%
| 0 | 100.0 % | 0 | 100.0 % | -99.34% |
Sales per region
EUR in Million | 2021 | Weight | 2022 | Weight | Delta |
---|---|---|---|---|---|
France
100.0
%
| 0 | 100.0 % | 0 | 100.0 % | -99.34% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Hugo Brugière
CEO | Chief Executive Officer | - | 22-11-07 |
Founder | - | 06-12-31 | |
Melissa Israel
CTO | Chief Tech/Sci/R&D Officer | - | 20-11-30 |
Philippe Rinaudo
CTO | Chief Tech/Sci/R&D Officer | - | 15-11-30 |
Xavier Paoli
COO | Chief Operating Officer | - | 14-03-31 |
Gilbert Wagener
CTO | Chief Tech/Sci/R&D Officer | - | 23-06-14 |
Joshua Schafer
BRD | Director/Board Member | 53 | 20-06-30 |
Antoine Gravelle
LAW | General Counsel | - | 22-06-30 |
Raj Thota
PRN | Corporate Officer/Principal | - | 21-10-18 |
Abhijit Pangu
LAW | General Counsel | - | 21-10-18 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
James Kuo
BRD | Director/Board Member | 58 | 22-06-15 |
Director/Board Member | 76 | 20-07-16 | |
Director/Board Member | 64 | 23-07-09 | |
Hugo Brugière
CEO | Chief Executive Officer | - | 22-11-07 |
Joshua Schafer
BRD | Director/Board Member | 53 | 20-06-30 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 78 | 77 ( 99.00 %) | 0 | 99.00 % |
Company contact information
Sector
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-98.22% | 6.71K | |
+40.73% | 739B | |
+32.83% | 598B | |
-6.30% | 353B | |
+15.15% | 318B | |
+4.05% | 285B | |
+15.00% | 240B | |
+9.78% | 210B | |
-5.52% | 206B | |
+6.17% | 164B |
- Stock Market
- Equities
- ALPHA Stock
- Company Pharnext SCA